Literature DB >> 18239278

Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein.

Jun-Sheng Wang1, Hao-Jie Zhu, Bryan Bradford Gibson, John Seth Markowitz, Jennifer Lyn Donovan, Carl Lindsay DeVane.   

Abstract

The ATP-binding cassette (ABC) transporter protein subfamily B1 line (ABCB1) transporter P-glycoprotein (P-gp) plays an important role in the blood-brain barrier limiting a broad spectrum of substrates from entering the central nervous system. In the present study, the transport activity of P-gp for sertraline, desmethylsertraline, bupropion, and the major metabolites of bupropion, threo-amino alcohol (TB), erythro-amino alcohol (EB), and hydroxy metabolite (HB) was studied using an ATPase assay in expressed human P-gp membranes by measuring concentrations of inorganic P(i) in expressed human P-gp membranes. Verapamil was included as a positive control. The Michaelis-Menten equation was used for characterizing the kinetic data. Sertraline and desmethylsertraline showed high affinity for P-gp. The V(max)/K(m) values of sertraline (1.6 min(-1) x 10(-3)) and desmethylsertraline (1.4 min(-1) x 10(-3)) were comparable with that of verapamil (1.7 min(-1) x 10(-3)). Bupropion and its three metabolites showed very weak affinity for P-gp, with V(max)/K(m) values lower than 0.01 min(-1) x 10(-3). The results of the present study indicate that sertraline and desmethylsertraline have high affinity for P-gp, whereas bupropion and its three major metabolites TB, EB, and HB have very weak affinity for P-gp. These findings may help to explain observed drug-drug interactions among antidepressants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18239278      PMCID: PMC2666302          DOI: 10.1248/bpb.31.231

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  27 in total

Review 1.  Mechanism of action of antidepressant medications.

Authors:  J P Feighner
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

Review 2.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter.

Authors:  S V Ambudkar; S Dey; C A Hrycyna; M Ramachandra; I Pastan; M M Gottesman
Journal:  Annu Rev Pharmacol Toxicol       Date:  1999       Impact factor: 13.820

3.  Placental passage of antidepressant medications.

Authors:  Victoria Hendrick; Zachary N Stowe; Lori L Altshuler; Sun Hwang; Emily Lee; Desiree Haynes
Journal:  Am J Psychiatry       Date:  2003-05       Impact factor: 18.112

4.  A population-based assessment of the potential interaction between serotonin-specific reuptake inhibitors and digoxin.

Authors:  David N Juurlink; Muhammad M Mamdani; Alexander Kopp; Nathan Herrmann; Andreas Laupacis
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

5.  Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice.

Authors:  Jun-Sheng Wang; C Lindsay DeVane; B Bryan Gibson; Jennifer L Donovan; John S Markowitz; Hao-Jie Zhu
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

6.  The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein.

Authors:  Jun-Sheng Wang; Ying Ruan; Robin M Taylor; Jennifer L Donovan; John S Markowitz; C Lindsay DeVane
Journal:  Int J Neuropsychopharmacol       Date:  2004-12       Impact factor: 5.176

7.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

Authors:  R B Kim; M F Fromm; C Wandel; B Leake; A J Wood; D M Roden; G R Wilkinson
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

8.  Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.

Authors:  J W Polli; J L Jarrett; S D Studenberg; J E Humphreys; S W Dennis; K R Brouwer; J L Woolley
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

9.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

Authors:  A H Schinkel; E Wagenaar; C A Mol; L van Deemter
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

10.  Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

Authors:  U Mayer; E Wagenaar; B Dorobek; J H Beijnen; P Borst; A H Schinkel
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

View more
  16 in total

Review 1.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

Review 2.  Potential Influence of Centrally Acting Herbal Drugs on Transporters at the Blood-Cerebrospinal Fluid Barrier and Blood-Brain Barrier.

Authors:  Lilian W Kibathi; SoHyun Bae; Scott R Penzak; Parag Kumar
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-12       Impact factor: 2.441

3.  Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion.

Authors:  Sarah J Hemauer; Svetlana L Patrikeeva; Xiaoming Wang; Doaa R Abdelrahman; Gary D V Hankins; Mahmoud S Ahmed; Tatiana N Nanovskaya
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

Review 4.  Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings.

Authors:  Fionn E O'Brien; Timothy G Dinan; Brendan T Griffin; John F Cryan
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

5.  The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis.

Authors:  Georgios Schoretsanitis; Olav Spigset; Julia C Stingl; Kristina M Deligiannidis; Michael Paulzen; Andreas A Westin
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-04-10       Impact factor: 4.481

6.  Antidepressant transfer into amniotic fluid, umbilical cord blood & breast milk: A systematic review & combined analysis.

Authors:  Georgios Schoretsanitis; Andreas A Westin; Julia C Stingl; Kristina M Deligiannidis; Michael Paulzen; Olav Spigset
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2021-01-02       Impact factor: 5.067

7.  PharmGKB summary: sertraline pathway, pharmacokinetics.

Authors:  Rachel Huddart; J Kevin Hicks; Laura B Ramsey; Jeffrey R Strawn; D Max Smith; Margarita Bobonis Babilonia; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2020-02       Impact factor: 2.000

8.  Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment-free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design.

Authors:  Lisanne M Geers; Taichi Ochi; Natalya M Vyalova; Innokentiy S Losenkov; Diana Z Paderina; Ivan V Pozhidaev; German G Simutkin; Nikolay A Bokhan; Bob Wilffert; Daniël J Touw; Anton J M Loonen; Svetlana A Ivanova
Journal:  Hum Psychopharmacol       Date:  2021-11-17       Impact factor: 2.130

9.  Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.

Authors:  Marco Siccardi; Catia Marzolini; Kay Seden; Lisa Almond; Anna Kirov; Saye Khoo; Andrew Owen; David Back
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

10.  ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.

Authors:  A B Singh; C A Bousman; C H Ng; K Byron; M Berk
Journal:  Transl Psychiatry       Date:  2012-11-27       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.